Cunningham-Myrie Colette, Abdulkadri Abdullahi, Waugh Andre, Bortolusso Ali Susanna, King Lesley-Gaye, Knight-Madden Jennifer, Reid Marvin
Department of Community Health and Psychiatry, University of the West Indies, Mona, Kingston, Jamaica.
Department of Economics, University of the West Indies, Mona, Kingston, Jamaica.
Pediatr Blood Cancer. 2015 Oct;62(10):1862-4. doi: 10.1002/pbc.25563. Epub 2015 Apr 30.
We undertook a cost effectiveness analysis (CEA) of hydroxyurea (HU) in preventing stroke recurrence and/or death. We followed 43 children with sickle cell disease from 2000 to 2009 after having a first clinical stroke, of whom 10 opted for HU therapy. HU use led to decreased stroke recurrence and death without significantly increasing the annual cost of care per patient (J$83,250 vs. J$76,901, P = 0.491). The incremental cost effectiveness ratio (ICER) for prevention of stroke recurrence amounted to J$169,238 (US$1,900), while that for death prevention equalled J$635,843 (US$7,140). HU may be recommended when safe and affordable transfusion therapy is not feasible.
我们对羟基脲（HU）预防中风复发和/或死亡进行了成本效益分析（CEA）。2000年至2009年，我们对43例首次发生临床中风后的镰状细胞病患儿进行了随访，其中10例选择了HU治疗。使用HU可降低中风复发率和死亡率，且未显著增加每位患者的年度护理成本（83250牙买加元对76901牙买加元，P = 0.491）。预防中风复发的增量成本效益比（ICER）为169238牙买加元（1900美元），预防死亡的ICER为635843牙买加元（7140美元）。当安全且负担得起的输血治疗不可行时，可推荐使用HU。
